Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

The gov­ern­ment’s wait­ing pe­ri­od for Mer­ck’s $10.8 bil­lion Prometheus Bio­sciences buy­out ex­pired on Mon­day, mean­ing the com­pa­nies can pro­ceed to close the deal, ac­cord­ing to an SEC fil­ing.

Prometheus an­nounced the merg­er last month af­ter field­ing in­ter­est from sev­er­al oth­er phar­ma com­pa­nies, in­clud­ing Ab­b­Vie and Bris­tol My­ers Squibb, ac­cord­ing to a Bloomberg re­port. It gives Mer­ck PRA023, an ex­per­i­men­tal an­ti-TL1A an­ti­body for in­flam­ma­to­ry bow­el dis­ease that Mer­ck ex­pects will play a big role in its fu­ture be­yond Keytru­da’s patent cliff.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER